GNI Group Ltd Company Review & Valuation

2160
Tokyo Stock Exchange
Latest Price
1.62kJPY
Market Capitalization
77.13bJPY

About GNI Group Ltd

GNI Group Ltd.

researches, develops, manufactures, and sells pharmaceutical drugs and traditional Chinese medicines in Japan and internationally.

The company provides Etuary for the treatment of idiopathic pulmonary fibrosis.

It is also developing Etuary for the treatment of radiation pneumonitis, which is in pilot study for Phase III clinical trials; Tamibarotene, a product for treating acute promyelocytic leukemia; and F351 that is in Phase II clinical trial for the treatment of liver fibrosis.

In addition, the company is developing Etuary for the treatment of diabetic nephropathy and connective tissue disease associated interstitial lung disease; and F573 for acute liver failure and acute-on-chronic liver failure.

Further, it is developing diabetic nephropathy; and connective tissue disease associated interstitial lung disease, which are in investigational new drug application stage.

GNI Group Ltd.

was founded in 2001 and is headquartered in Tokyo, Japan.

Industry
HQ Location
Tokyo, Japan

Stock Price

Price data not available for GNI Group Ltd.

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl